Single Cell Technology to present at Biotech showcase

SAN JOSE, CA, December 26, 2012

Single Cell Technology, Inc., a biotechnology company focused on discovering and optimizing therapeutic antibodies from diverse and unusual hosts, today announced that Jim Bowlby, Chief Operations Officer, will present at the Biotech Showcase 2013, held January 7-9, 2013, in San Francisco, CA. After Mr. Bowlby provides details on recent intellectual property and partnering milestones, both he and Dr. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer, will be available to respond to questions and participate in one-on-one meetings with potential partners and investors attending the conference.

​Event: Biotech Showcase 2013
Date: Wednesday, January 9, 2013
Time: 4:00 pm PST
Place: Parc 55 Wyndham, San Francisco, CA


Single Cell Technology, Inc. (SCT) has pioneered a new approach to analysing antibodies and mRNA from individual antibody secreting cells. Antibodies are rapidly screened against multiple molecules to measure their affinity and specificity and mRNA from the cognate light and heavy chains are sequenced by Next Generation Sequencing (NGS) technology and correctly paired. In addition to human and mouse cells, SCT’s technology can be applied to any host that concentrates plasma cells in lymphoid tissues. Founders Chun-Nan Chen and Jim Bowlby integrated advances in multiple disciplines, such as wafer fabrication, molecular biology, precision mechanical engineering, nanotechnology, image processing, NGS, and bioinformatics. SCT’s approach substantially decreases the time and investment needed to discover high quality therapeutic and diagnostic antibodies.


​This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not beregarded as a representation that either of the companies’ plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These factors include, but are not limited to, uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and the evolution of the market for innovative antibody discovery. The companies undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.